Cell Culture Instruments Market (2026 - 2033)

Cell Culture Instruments Market Summary

The global cell culture instruments market size was valued at USD 8.0 billion in 2025 and is projected to grow from USD 8.8 billion in 2026 to USD 19.4 billion by 2033, at a CAGR of 12.0% from 2026 to 2033. The market in North America dominated with a revenue share of 35.7% in 2025. The market growth is driven by the increasing adoption of advanced cell culture technologies, the growing demand for biopharmaceuticals and biologics, and the expanding applications of cell culture instruments in drug discovery, regenerative medicine, vaccine development, and pharmaceutical research.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

To learn more about this report, Download Free Sample Report

Market Dynamics

Rising adoption of cell-based research technologies across pharmaceutical and biotechnology applications is contributing to the expansion of the cell culture instruments industry. Growing adoption of automated cell culture systems and bioreactors is enabling greater process control, reproducibility, scalability, and efficiency in research and biomanufacturing. In addition, expanding use of three-dimensional cell cultures, organoids, and other human-relevant models for drug screening, toxicity assessment, and disease research is supporting market growth.

Market Concentration & Characteristics

The degree of innovation in the global market is high, driven by advances in live-cell imaging, 3D cell culture analysis, confocal microscopy, and high-throughput monitoring technologies. For instance, in July 2025, Sartorius launched the Incucyte CX3 Live-Cell Analysis System, featuring confocal fluorescence imaging for continuous analysis of complex 3D cell cultures and real-time analysis of up to six microplates in parallel. The system enables non-invasive monitoring of cell growth, morphology, and phenotypic changes while maintaining cultures in a controlled environment, enhancing the efficiency and quality of 3D cell culture research.

“3D cell research is rapidly growing, yet scientists still lack the necessary tools or expertise to develop, validate, and perform 3D cell assays at scale. We developed the Incucyte CX3 system and paired it with easy-to-use software to make studying 3D models more accessible than ever. Now, every scientist can gain a deeper understanding of cell health, growth, and morphology, while benefiting from throughput that is unmatched in the market.”

Lindy O’Clair, Product Manager of Incucyte Systems at Sartorius.

The cell culture instruments industry is witnessing moderate M&A activity, as companies seek to expand their capabilities in automated cell cultivation and bioreactor technologies. For instance, in December 2024, Demcon acquired a majority stake in Orgonex, a Utrecht University spin-off that developed a compact bioreactor specifically for organoid cultivation. The acquisition strengthened Demcon’s cell culture technology portfolio and provided resources for further product development and commercialization. Moreover, Orgonex’s bioreactor is designed to improve cultivation efficiency and can be integrated into existing laboratory infrastructure, supporting its adoption in academic, biotechnology, and pharmaceutical research.

To learn more about this report, Download Free Sample Report

The global market is increasingly influenced by regulatory requirements related to equipment quality, contamination control, sterilization, calibration, and process consistency. These requirements encourage manufacturers to develop instruments that support controlled and reproducible cell culture workflows. Furthermore, regulatory expectations for equipment used in biopharmaceutical manufacturing emphasize monitoring critical parameters and maintaining equipment in a suitable condition to ensure product quality and minimize contamination risks.

The market is witnessing product expansion with the introduction of advanced bioreactor systems that enhance flexibility, automation, and process monitoring. For instance, in March 2025, Culture Biosciences launched the Stratyx 250, a mobile, cloud-integrated bioreactor specifically designed for cell culture process development. The system combines automated control, remote monitoring, and cloud-based data visibility, expanding access to the flexible, digitally connected bioreactor solutions for cell culture research and process development.

“The biotech and biopharmaceutical market segments are experiencing a major shift toward cloud-powered, modular bioprocessing, and these companies need hardware and software that can keep up. With a five-month ROI timeline and a plug-and-play scalable architecture, our platform offers a cost-effective, flexible alternative to traditional bioreactors, helping companies accelerate development and reduce costs without compromising on quality.”

- Chris Williams, CEO of Culture Biosciences

The cell culture instruments industry is witnessing regional expansion as manufacturers broaden their operations, distribution networks, and technical support across key biotechnology and pharmaceutical markets. Companies are expanding into emerging markets to address growing demand for cell culture systems, incubators, bioreactors, cell expansion systems, cell analysis instruments, and cell processing equipment, improving product availability and supporting growth in life sciences research and biopharmaceutical development.

Analyst Perspective

The cell culture instruments market is expected to experience moderate growth, driven by the increasing need for efficient, standardized, and scalable cell culture workflows across research and bioprocessing applications. As end users seek greater operational efficiency, demand is expected to shift toward instruments that deliver consistent performance, enable flexible workflow integration, and reduce manual intervention. The market is also likely to benefit from growing emphasis on simplifying complex cell culture processes and improving the utilization of laboratory resources. Manufacturers are focusing on developing modular, application-oriented solutions that accommodate changing throughput requirements while enabling seamless integration across cell culture workflows.

Product Insights

The cell culture systems segment led the market with the largest revenue share of 39.7% in 2025, supported by increasing adoption of automated systems for cell cultivation and processing. For instance, in September 2026, Shibuya Corporation delivered its automated cell culture system for autologous cell banks to MEDEZE in Thailand. The system integrates robotic cell processing with approximately 100 independent incubation units and automates processes including media exchange, cell seeding, and passaging. Moreover, the system supports commercial-scale cell manufacturing with a processing capacity of up to 24 batches per day, highlighting the growing adoption of automated cell culture systems.

The cell processing instruments segment is expected to grow at the fastest CAGR during the forecast period, driven by the increasing adoption of automated cell-processing technologies. For instance, in January 2025, Curiox Biosystems launched the C-Free Pluto ALPHA, an automated cell washing system designed to replace conventional centrifuge-based washing of suspension cells and beads. The system uses a pipette head to provide consistent cell washing while reducing manual handling. The launch highlights the growing adoption of automated cell processing instruments across cell-based research and processing workflows.

“The Curiox C- Free Pluto ALPHA combines affordability, simplicity, and precision, enabling labs of all sizes to achieve consistent, reliable results while saving time and resources. This device embodies our commitment to providing accessible automation solutions that elevate research capabilities.”

-Dr. Namyong Kim, CEO & CTO at Curiox Biosystems

Cell Culture Insights

The mammalian cell culture segment dominated the market, with the largest revenue share of 56.7% in 2025, driven by the growing use of mammalian cells in biopharmaceutical production, particularly for monoclonal antibodies and other recombinant proteins. For instance, in September 2025, FUJIFILM Biotechnologies opened its commercial-scale cell culture manufacturing site in North Carolina, featuring eight 20,000-L mammalian cell culture bioreactors for drug substance and drug product manufacturing. The facility highlights the expanding adoption of large-scale mammalian cell culture for biopharmaceutical manufacturing.

"Fujifilm's total global investment of over $8 billion to expand our contract development and manufacturing organization (CDMO) business underscores our unwavering commitment to advancing life sciences for our partners, people, and patients. Our new commercial-scale manufacturing hub in the U.S. highlights Fujifilm’s dedication to supporting our partners in delivering biologic medicines targeting complex diseases.”

- Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio CDMO Division, FUJIFILM Corporation, Japan, and chairman, FUJIFILM Biotechnologies

The stem cell culture segment is expected to grow at the fastest CAGR during the forecast period, driven by increasing use of stem cell culture systems for regenerative medicine, drug discovery, disease modeling, and toxicology research. The development of chemically defined xeno-free, scalable, and automated culture platforms is further supporting the expansion of stem cell cultivation workflows. According to an article published in Frontiers in Toxicology in December 2025, advancements in human pluripotent stem cell culture have enabled scalable and GMP-compatible culture systems, while automation and 3D bioprocessing are improving standardization, quality control, and throughput.

Application Insights

The biopharmaceutical production segment led the market with the largest revenue share of 44.6% in 2025. The segment is driven by the increasing use of cell culture technologies the produce monoclonal antibodies, recombinant proteins, vaccines, and other biologics. Growing demand for biologics and the expansion of biomanufacturing capacity are further supporting the adoption of advanced cell culture systems and processes for biopharmaceutical production.

The cell & gene therapy segment is projected to grow at the fastest CAGR during 2026-2033, driven by increasing demand for scalable, automated, and controlled cell culture systems for the manufacturing of advanced therapies. These instruments support critical processes such as cell expansion, genetic modification, and culture monitoring while improving processing consistency and reducing manual intervention. For instance, in June 2025, Cellular Origins announced a collaboration with Thermo Fisher Scientific to combine Thermo Fisher’s cell culture and processing technologies with Cellular Origins’ Constellation robotic platform for fully automated manufacturing of cell and gene therapies at an industrial scale. The collaboration highlights the growing adoption of automated cell culture instruments in cell and gene therapy manufacturing.

"CGT manufacturing is evolving at a historic pace to catch up with therapeutic development, as well as to serve the rollout of the number of imminent therapeutic approvals for widespread indications. Increasing automation, manufacturing, and throughput, and reducing the need for human labor, will be essential for the CGT sector to continue advancing. As a result, we are working with Cellular Origins to provide a full industrialized manufacturing service to the sector. Our VIOS AxD CO2 incubator is designed for just such a system.”

- Douglas Wernerspach, Sr. Business Director/General Manager - CO2 Incubators and Biological Safety Cabinets, Thermo Fisher Scientific

End Use Insights

The pharmaceutical & biotechnology companies segment led the market with the largest revenue share of 46.2% in 2025. The growth is driven by the increasing use of cell culture instruments for biopharmaceutical development, process optimization, and large-scale biologics manufacturing. The growing adoption of automated and scalable cell culture systems is further supporting demand from pharmaceutical and biotechnology companies. For instance, in March 2025, ABEC introduced its Advanced Therapy Bioreactor (ATB), a single-use, closed, and fully automated bioreactor designed for cell expansion from 0.2 L to 10 L, and it has been demonstrated for applications involving T cells, CD34+ stem cells, HEK293, and CHO cell lines. The development highlights the growing use of advanced cell culture instruments in pharmaceutical and biotechnology manufacturing workflows.

“The ATB introduction is another milestone in ABEC’s 50-year history of bioprocess innovation. Similar to our solutions for recombinant protein manufacturing, the ATB promises to address the most difficult challenges in advanced therapy manufacturing and accelerate our partners’ time to clinic and market.”

- Scott Pickering, CEO of ABEC

To learn more about this report, Download Free Sample Report

The CROs & CDMOs segment is projected to grow at the fastest CAGR during the forecast period, supported by increasing outsourcing of cell culture and bioprocessing activities to specialized service providers. CROs and CDMOs increasingly utilize cell culture instruments for cell expansion, media exchange, monitoring, and process optimization across research and biopharmaceutical manufacturing workflows. Moreover, the growing demand for scalable, standardized cell culture processes is driving the adoption of advanced cell culture instruments among CROs and CDMOs.

Regional Insights

The North America cell culture instruments market held the largest revenue share of 35.7% in 2025, driven by expanding biopharmaceutical R&D and the adoption of advanced cell culture and bioprocessing technologies. For instance, in November 2024, Sartorius opened a Center for Bioprocess Innovation in Marlborough, Massachusetts, featuring research laboratories, process-development facilities, and customer demonstration and training capabilities for bioprocessing workflows. The center strengthens regional access to technologies and expertise for cell culture process development, optimization, and scale-up, supporting the adoption of cell culture instruments.

“Cell and gene therapies and other novel treatments offer promising solutions for patients with previously incurable diseases. However, these modalities are still in their infancy and often require the development of new manufacturing processes in order to become more efficient and less costly. This cutting-edge innovation center enables us to leverage our bioprocessing tools and workflows expertise, ultimately accelerating and simplifying our customers’ path to clinical trials.”

-René Fáber, CEO of Sartorius Stedim Biotech.

To learn more about this report, Download Free Sample Report

U.S. Cell Culture Instruments Market Trends

The cell culture instruments market in the U.S. accounted for the largest revenue share in North America in 2025, driven by the increasing adoption of automated systems to standardize and scale cell culture workflows. For instance, in August 2025, Molecular Devices unveiled a major upgrade to its CellXpress.ai Automated Cell Culture System, integrating rocking incubation to support the development and long-term maintenance of brain organoids. The upgrade expands automated cell culture capabilities for complex 3D models and supports more consistent and scalable cell culture workflows in U.S. research applications.

“With this new automation feature, we’re freeing scientists from the relentless demands of long-term brain organoid growth. The CellXpress.ai cell culture system streamlines these complex workflows so researchers can focus on what matters most: accelerating insights into diseases like Alzheimer’s and Parkinson’s and advancing a future where human-relevant models are the norm.”

-Mary Duseau, President of Molecular Devices

Europe Cell Culture Instruments Market Trends

The cell culture instruments market in Europe is anticipated to grow at a substantial CAGR over the forecast period, supported by increasing adoption of real-time monitoring technologies for controlled cell culture and bioprocessing applications. For instance, in December 2025, Hamilton launched GlucoSense, a reusable in situ glucose sensor designed to provide continuous, real-time glucose measurements directly inside mammalian cell culture bioreactors. Moreover, this technology enhances monitoring and control of cell culture processes, supporting the adoption of advanced analytical instruments for cell culture applications.

"Bioprocessing teams have been asking for a simple, reliable way to measure glucose in situ for years. With GlucoSense, we're giving customers real-time visibility into one of the most critical parameters in mammalian cell culture without the complexity, drift, or calibration burden that has limited previous technologies. And we've designed the product roadmap to support every step of the development lifecycle, from R&D to GMP manufacturing."

-Giovanni Campolongo, Senior Market Segment Manager at Hamilton

The UK cell culture instruments market is driven by increasing adoption of scalable bioreactor technologies for advanced cell culture and stem cell research. For instance, in March 2026, UK-based REPROCELL expanded its product portfolio with the BioThrust ComfyCell Incu bioreactor platform, a 300 mL single-use system designed for intensified and scalable cultivation of sensitive cells, including iPSC spheroids and immune cells. The commercial availability of the platform strengthens access to advanced bioreactor technology for cell culture applications.

The cell culture instruments market in Germany is anticipated to grow significantly over the forecast period, supported by increasing adoption of specialized equipment for mammalian suspension-cell cultivation and bioprocessing. For instance, in September 2024, Hamburg-based Eppendorf launched the CellXpert CS220 CO₂ Incubator Shaker, developed specifically for mammalian suspension-cell culture, including CHO and HEK293 cells. The instrument incorporates an integrated 180°C sterilization routine and supports applications such as cell-line development, protein expression, viral vector production, and bioreactor inoculum preparation, thereby strengthening Germany’s commercial cell culture instrumentation landscape.

“Our new CellXpert CS220 was developed specifically to speed up mammalian shake flask culture projects and to meet the industry’s increasing need for higher contamination prevention standards. We are happy to welcome the new member of our CellXpert family and to expand our successful cell culture portfolio, including CO2 incubators, shakers, high-speed centrifuges, and bioprocess equipment”

-Maria Mattern, responsible for innovations of the Eppendorf shaker and CO2 incubator portfolio.

Asia Pacific Cell Culture Instruments Market Trends

The cell culture instruments market in the Asia Pacific is expected to grow at the fastest CAGR of 14.2% during the forecast period, supported by increasing cell and gene therapy research and rising adoption of advanced bioprocessing technologies. The growing production of monoclonal antibodies, vaccines, biosimilars, and other biologics across the region is driving demand for bioreactors, incubators, centrifuges, and other cell culture equipment. In addition, increasing investments in local bioprocessing infrastructure and the adoption of single-use and automated technologies are supporting the expansion of cell culture workflows across research, process development, and commercial manufacturing applications.

The China cell culture instruments market is expected to grow significantly over the forecast period, supported by expanding biopharmaceutical manufacturing, increasing cell therapy activities, and rising adoption of scalable cell culture technologies. For instance, in April 2025, Beijing-based Cytoniche launched the 3D FloTrix megaSPIN single-use bioreactor system for three-dimensional cell culture. The system is designed to support scalable stem cell expansion while addressing limitations associated with conventional 2D culture and scale-up processes. The launch reflects growing demand for single-use bioreactor technologies supporting higher-capacity and standardized cell expansion workflows

The cell culture instruments market in Japan is experiencing rapid growth, driven by expanding cell and gene therapy development, growing biopharmaceutical research, and rising adoption of scalable cell culture technologies. For instance, in June 2025, Japan-based PHCbi launched the scale-X nexo fixed-bed bioreactor system and Skaia Vision software for early research and cell culture process development. The system supports efficient cell expansion and enables monitoring and optimization of culture processes, facilitating the transition from laboratory-scale research toward commercial manufacturing. The development reflects increasing demand for advanced bioreactor systems in Japan’s cell therapy and bioprocessing sectors.

Latin America Cell Culture Instruments Market Trends

The cell culture instruments market in Latin America is expected to grow steadily over the forecast period, supported by expanding biopharmaceutical research and manufacturing, increasing cell and gene therapy activities, and growing investment in biotechnology infrastructure. The rising development of vaccines, biologics, and advanced therapies is increasing the need for controlled and scalable cell culture workflows across research and manufacturing facilities. In addition, efforts to strengthen regional biomanufacturing capabilities and expand access to advanced laboratory infrastructure are supporting the adoption of bioreactors, incubators, cell counters, and automated cell culture systems across the region.

MEA Cell Culture Instruments Market Trends

The cell culture instruments market in the Middle East & Africa is growing steadily, supported by expanding biopharmaceutical manufacturing, increasing cell and gene therapy research, and government initiatives to strengthen biotechnology capabilities. In Saudi Arabia, Vision 2030 and the National Biotechnology Strategy are promoting vaccine and biopharmaceutical manufacturing, genomic research, and biotechnology infrastructure, supporting demand for advanced cell culture technologies. In addition, investments in biologics and advanced-therapy manufacturing are creating opportunities for bioreactors, incubators, and automated cell culture systems across the region.

Key Cell Culture Instruments Company Insights

The cell culture instruments industry is highly competitive, with key players focusing on cell culture systems, bioreactors, cell expansion systems, and cell analysis and processing instruments. Companies are strengthening their market position through product launches, technological advancements, strategic collaborations, capacity expansion, and the development of integrated cell culture and analysis solutions. Moreover, competitive positioning depends on product offerings, technological capabilities, accuracy, scalability, geographic presence, customer base, and applications across biopharmaceutical production, cell and gene therapy, research and development, tissue engineering and regenerative medicine, and other cell culture applications.

Key Cell Culture Instruments Companies

The following key companies have been profiled for this study on the cell culture instruments market:

• Thermo Fisher Scientific Inc.

• Danaher Corporation

• Sartorius AG

• Merck KGaA

• Corning Incorporated

• Eppendorf SE

• BD

• Agilent Technologies, Inc.

• Miltenyi Biotec

• Terumo Corporation

• Bio-Rad Laboratories, Inc.

• Revvity

Recent Developments:

• In April 2026, Sartorius AG launched CellCelector CLD, an automated imaging and cell isolation platform for monoclonal cell line development. The system enables high-speed screening, automated clone verification, and gentle retrieval of selected cells, supporting faster cell-line development and downstream expansion.

“What used to take months can now be completed in approximately seven weeks. The CellCelector CLD gives teams the confidence to move from screening to stable, high-producing cell lines faster than standard workflows, with full traceability at every step.”

-Darius Wilson, Product Manager of CellCelector Systems at Sartorius.

• In May 2025, BD launched the FACSDiscover A8 Cell Analyzer, combining spectral flow cytometry with real-time cell imaging. The instrument enables high-throughput multiparameter cell analysis, allowing researchers to characterize cell properties, morphology, spatial information, and biological markers, and to support advanced immunophenotyping, biomarker discovery, and cell biology research.

• In May 2025, Thermo Fisher Scientific Inc. introduced the 5 L DynaDrive Single-Use Bioreactor, a bench-scale bioreactor designed for scalable upstream process development. The system supports cell culture applications while providing consistent mixing, mass transfer, process control, and scalability from laboratory development to larger-scale commercial manufacturing.

“The introduction of the 5L DynaDrive marks a significant advancement in our commitment to helping customers maximize productivity and accelerate time to market. With 25 years of experience in single-use technology, we are dedicated to meeting our customers' evolving needs. Our trusted innovations provide seamless scalability and enhanced efficiency, enabling customers to streamline their bioprocessing workflows and successfully develop and commercialize life-saving therapies."

- Ray Mercier, president of Thermo Fisher’s single-use technologies business.

Global Cell Culture Instruments Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global cell culture instruments market report based on the product, cell culture, application, end use and region

• Product Outlook (Revenue, USD Billion, 2021 - 2033)

  • Cell Culture Systems

    • Cell Culture Incubators

    • Bioreactors

    • Cell Expansion Systems

    • Other Cell Culture Systems

  • Cell Analysis Instruments

    • Cell Counters

    • Cell Analyzers

    • Cell Imaging Systems

  • Other Cell Analysis Instruments

    • Cell Processing Instruments

    • Cell Separation Systems

    • Cell Washing Systems

    • Cell Harvesting Systems

    • Other Cell Processing Instruments

  • Other Cell Culture Instruments

• Cell Culture Outlook (Revenue, USD Billion, 2021 - 2033)

  • Mammalian Cell Culture

  • Microbial Cell Culture

  • Stem Cell Culture

  • Other Cell Culture

• Application Outlook (Revenue, USD Billion, 2021 - 2033)

  • Biopharmaceutical Production

  • Cell & Gene Therapy

  • Research & Development

  • Tissue Engineering & Regenerative Medicine

  • Other Applications

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Pharmaceutical & Biotechnology Companies

  • Academic & Research Institutes

  • CROs & CDMOs

  • Hospitals & Clinical Laboratories

  • Other End Users

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The cell culture instruments marketfigures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with eachcell culture instruments segment quantified using the revenue-capture definitions in the table below.